Other

Total cash equivalents and marketable securities, Fair Value

Vertex Pharmaceuticals Total cash equivalents and marketable securities, Fair Value increased by 0.6% to $10.07B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.5%, from $8.09B to $10.07B. Over 2 years (FY 2023 to FY 2025), Total cash equivalents and marketable securities, Fair Value shows relatively stable performance with a -1.8% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2023
Last reportedQ1 2026
Metric ID: other_cash_equivalents_debt_and_equity_securities_fair_value

Historical Data

10 periods
 Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$10.38B$11.26B$7.44B$8.15B$8.34B$8.09B$8.07B$8.29B$10.01B$10.07B
QoQ Change—+8.5%-33.9%+9.4%+2.4%-3.0%-0.3%+2.7%+20.9%+0.6%
YoY Change————-19.6%-28.1%+8.4%+1.7%+20.1%+24.5%
Range$7.44B – $11.26B
CAGR-1.3%
Avg YoY Growth+1.1%
Median YoY Growth+5.0%
Current Streak3 quarters growth

Frequently Asked Questions

What is Vertex Pharmaceuticals's total cash equivalents and marketable securities, fair value?
Vertex Pharmaceuticals (VRTX) reported total cash equivalents and marketable securities, fair value of $10.07B in Q1 2026.
How has Vertex Pharmaceuticals's total cash equivalents and marketable securities, fair value changed year-over-year?
Vertex Pharmaceuticals's total cash equivalents and marketable securities, fair value increased by 24.5% year-over-year, from $8.09B to $10.07B.
What is the long-term trend for Vertex Pharmaceuticals's total cash equivalents and marketable securities, fair value?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's total cash equivalents and marketable securities, fair value has grown at a -1.8% compound annual growth rate (CAGR), from $10.38B to $10.01B.